Biotechnology giant Amgen ( AMGN) said on Oct. 19 that it is laying off 380 employees in its research and development division. This represents about 6% of its total workforce.

The company said it is restructuring these operations in the effort to better allocate its research and development resources.

In its second quarter, Amgen spent 26% more in research to $808 million. In a statement, Amgen said it has experimental drugs moving into expensive, late-stage patient testing so it must shift some research and development resources to invest in the testing and other work related to getting the experimental medicines approved.

If you liked this article you might like

Cramer: Irma and Harvey Busted the Algos

Analysts Wrong on iPhone; Retail Not Going Away: Best of Cramer

Cramer: Retail Is Not Going Away; It's Just Going Different Places

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Cramer: Market Rushes to Refill Its Glass